A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cel
ENSAYO CLINICO COMERCIAL
Información del ensayo clínico
- Promotor: CELGENE INTERNATIONAL II SARL
- Fase: III
- Comienzo de la ejecución: 11/12/2020
- Fin de la ejecución: 30/07/2024
- IP: FRANCISCA HERNANDEZ MOHEDO